title: Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
abstract: The use of erlotinib throughout pregnancy has not been previously reported. We present the case of a 40 year-old female patient with stage IV lung adenocarcinoma, mediastinal, bone and cerebral metastasis, a EGFR mutation and no smoking history, who had begun first line treatment with erlotinib 150 mg once daily. After two and a half months of treatment a fourteen-week pregnancy was documented, and after informing on fetal risks secondary to erlotinib use and maternal risks secondary to treatment withholding, she decided to continue with treatment under clinical surveillance by both the oncology and obstetrics clinics. At thirty-three weeks gestation a live born 1600 g female was born by caesarean section without evidence of congenital malformations. Imaging assessment after eight months of treatment showed complete bone and central nervous system response and partial lung and mediastinal response. The patient is currently undergoing the 11th month of treatment and is asymptomatic, the baby is 4 months old and is in good health.
authors.affiliation: Clinical Oncology Group, Cancerology National Institute, E.S.E., Bogota, Colombia. govariv@hotmail.com
authors.forename: Giovanna
authors.initials: G
authors.lastname: Rivas
authors.forename: Nestor
authors.initials: N
authors.lastname: Llinás
authors.forename: Carlos
authors.initials: C
authors.lastname: Bonilla
authors.forename: Juan
authors.initials: J
authors.lastname: Rubiano
authors.forename: Javier
authors.initials: J
authors.lastname: Cuello
authors.forename: Natalia
authors.initials: N
authors.lastname: Arango
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001483:Base Sequence; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D009362:Neoplasm Metastasis; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy*; D011256:Pregnancy Outcome; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors